SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  For example, here is how to disable FireFox ad content blocking while on Silicon Investor.
Biotech / Medical : Trega Biosciences (TRGA), formerly HPIP

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: bob zagorin who wrote (144)1/4/2001 11:26:55 AM
From: Roger Folsom  Read Replies (1) of 152
 
Re the acquisition of Trega by Lion Biosciences: The press release says that Trega will be valued $35 million, or $1.35 per share, with the final exchange ratio depending on Lion's ADS share price, between $68 and $92. But does anyone here worked out what exchange ratio was used to get the $35 million and $1.35 per share, and whether the price used was $68, $92, the midpoint, or whatever Lion was at when the offer was made?

I'm very impressed by Trega's web site description of their technology, and I might want to continue to have that technology among my investments, but it's not clear to me whether getting Lion by buying more Trega would be more or less efficient than buying Lion directly.

Cordially, Roger Folsom
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext